Amir-Reza Abolhassani1, Gerold Schuler1, Michael Constantin Kirchberger1, Lucie Heinzerling2. 1. Department of Dermatology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany. 2. Department of Dermatology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany. Lucie.Heinzerling@uk-erlangen.de.
Abstract
PURPOSE: Immune checkpoint inhibitors (ICIs) are effective against a wide variety of cancers. However, they also induce a plethora of unique immune-related adverse events (irAEs). Since for many organ systems symptoms can be unspecific, differential diagnosis with progression of disease or infection may be difficult. C-reactive protein (CRP) has been suggested as a marker for infection. The purpose of this study was to evaluate the diagnostic value of CRP in differentiating infectious causes from autoimmune side effects induced by ICIs. METHODS: In order to investigate the role of CRP in irAEs, we screened our patient data base. Only events with full infectious workup were included. In total 88 events of irAEs in 37 melanoma patients were analyzed. CRP levels before and during irAEs were evaluated. Statistical analyses were conducted using the Chi-square test for categorical variables. RESULTS: At the onset of irAE, CRP rose in 93% of cases to a mean of 52.7 mg/L (CI 35.1-70.3) from 8.4 mg/L at baseline (normal < 5 mg/L) (P < 0.0001). Other causes of CRP elevation including infectious diseases were excluded, and procalcitonin (PCT) levels were normal in 92% of events. Importantly, in 42% of cases CRP elevations preceded clinical symptoms. CONCLUSION: CRP elevation can predict the onset of irAEs in patients treated with ICIs in the absence of infectious disease.
PURPOSE: Immune checkpoint inhibitors (ICIs) are effective against a wide variety of cancers. However, they also induce a plethora of unique immune-related adverse events (irAEs). Since for many organ systems symptoms can be unspecific, differential diagnosis with progression of disease or infection may be difficult. C-reactive protein (CRP) has been suggested as a marker for infection. The purpose of this study was to evaluate the diagnostic value of CRP in differentiating infectious causes from autoimmune side effects induced by ICIs. METHODS: In order to investigate the role of CRP in irAEs, we screened our patient data base. Only events with full infectious workup were included. In total 88 events of irAEs in 37 melanomapatients were analyzed. CRP levels before and during irAEs were evaluated. Statistical analyses were conducted using the Chi-square test for categorical variables. RESULTS: At the onset of irAE, CRP rose in 93% of cases to a mean of 52.7 mg/L (CI 35.1-70.3) from 8.4 mg/L at baseline (normal < 5 mg/L) (P < 0.0001). Other causes of CRP elevation including infectious diseases were excluded, and procalcitonin (PCT) levels were normal in 92% of events. Importantly, in 42% of cases CRP elevations preceded clinical symptoms. CONCLUSION:CRP elevation can predict the onset of irAEs in patients treated with ICIs in the absence of infectious disease.
Authors: Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson Journal: J Clin Oncol Date: 2018-02-14 Impact factor: 44.544
Authors: Giorgos Bamias; Ioanna Delladetsima; Marina Perdiki; Spyros I Siakavellas; Dimitrios Goukos; George V Papatheodoridis; George L Daikos; Helen Gogas Journal: Cancer Invest Date: 2017-05-26 Impact factor: 2.176
Authors: V Damuzzo; S Solito; L Pinton; E Carrozzo; S Valpione; J Pigozzo; R Arboretti Giancristofaro; V Chiarion-Sileni; S Mandruzzato Journal: Oncoimmunology Date: 2016-11-01 Impact factor: 8.110
Authors: Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Robert Cheng; Adam Cooper; James Kench; Geoff Watson; William Bye; Catriona McNeil; Nicholas Shackel Journal: J Gastroenterol Hepatol Date: 2015-04 Impact factor: 4.029
Authors: L Derosa; M D Hellmann; M Spaziano; D Halpenny; M Fidelle; H Rizvi; N Long; A J Plodkowski; K C Arbour; J E Chaft; J A Rouche; L Zitvogel; G Zalcman; L Albiges; B Escudier; B Routy Journal: Ann Oncol Date: 2018-06-01 Impact factor: 32.976
Authors: Arjun V Balar; Daniel Castellano; Peter H O'Donnell; Petros Grivas; Jacqueline Vuky; Thomas Powles; Elizabeth R Plimack; Noah M Hahn; Ronald de Wit; Lei Pang; Mary J Savage; Rodolfo F Perini; Stephen M Keefe; Dean Bajorin; Joaquim Bellmunt Journal: Lancet Oncol Date: 2017-09-26 Impact factor: 41.316
Authors: Sarah Chuzi; Fabio Tavora; Marcelo Cruz; Ricardo Costa; Young Kwang Chae; Benedito A Carneiro; Francis J Giles Journal: Cancer Manag Res Date: 2017-06-14 Impact factor: 3.989
Authors: Louise E Daly; Derek G Power; Áine O'Reilly; Paul Donnellan; Samantha J Cushen; Kathleen O'Sullivan; Maria Twomey; David P Woodlock; Henry P Redmond; Aoife M Ryan Journal: Br J Cancer Date: 2017-01-10 Impact factor: 7.640
Authors: Colby S Shemesh; Phyllis Chan; Fatema A Legrand; David S Shames; Meghna Das Thakur; Jane Shi; Lorna Bailey; Shweta Vadhavkar; Xian He; Wei Zhang; René Bruno Journal: Pharmacol Res Perspect Date: 2020-12